Hemophilia News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Hemophilia Pipeline Highlights - 2017-2020 Update - Business Wire - Business Wire (press release)



Hemophilia Pipeline Highlights - 2017-2020 Update - Business Wire 
Business Wire (press release)
The latest report from, Hemophilia Pipeline Highlights - 2017 Update, provides most up-to-date information on key pipeline products in the global Hemophilia market. It covers emerging therapies for Hemophilia in active clinical development stages ...

and more » 


Oxford BioMedica, Bioverativ to Develop Lentiviral Vectors for Hemophilia Gene Therapy - Genetic Engineering & Biotechnology News



The Pharma Letter
 
Oxford BioMedica, Bioverativ to Develop Lentiviral Vectors for Hemophilia Gene Therapy 
Genetic Engineering & Biotechnology News
?Bioverativ's investment in hemophilia gene therapy underlines the potential of lentiviral vectors for use for in vivo gene therapy. Dawson added that the agreement with Bioverativ ?demonstrates Oxford BioMedica's strategy of building multiple ...
Bioverativ taps new manufacturer as it steps out of Biogen's shadow BioPharma Dive
Oxford BioMedica set to earn $100 million in deal with Sanofi takeover target The Pharma Letter

all 14 news articles » 


Save One Life Funding Care for Hemophilia in Developing Countries - Borgen Project



Borgen Project
 
Save One Life Funding Care for Hemophilia in Developing Countries 
Borgen Project
People with hemophilia, a genetic disorder, are born with dysfunctional or deficient clotting factors in their blood. Though several types of hemophilia exist, the two most common are hemophilia A, where the body lacks sufficient amounts of clotting ...

 


Hemophilia B Medication Made Available to Pharmacies - Pharmacy Times



Pharmacy Times
 
Hemophilia B Medication Made Available to Pharmacies 
Pharmacy Times
Officials with Novo Nordisk announced that a new medicine for treating hemophilia B, Rebinyn Coagulation Factor X (recombinant), GlycoPEGlated, has been made available to pharmacies. The drug was FDA-approved in May 2017 for treating and controlling ...
Hemophilia B Therapy Rebinyn Available in United States Hemophilia News Today

all 2 news articles » 


Hemlibra's Remarkable Efficacy A Beacon for Hemophilia Patients - Managed Care magazine



Managed Care magazine
 
Hemlibra's Remarkable Efficacy A Beacon for Hemophilia Patients 
Managed Care magazine
The two most common forms of hemophilia are inherited and are named hemophilia A and hemophilia B. Hemophilia, which is sometimes called classic hemophilia, is the result of a deficiency of factor VIII. It occurs in about one in every 5,000 to 10,000 ...

 


Roche hemophilia drug lowers costs despite high price: ICER - Reuters



Reuters
 
Roche hemophilia drug lowers costs despite high price: ICER 
Reuters
Hemophilia is a rare bleeding disorder in which a clotting protein is missing or does not function normally. Roche plans to charge about $482,000 for the first year of treatment and $448,000 a year after that. To avoid joint damage and other ...
CHMP Backs First-in-Class Drug Emicizumab for Hemophilia A Medscape

all 4 news articles » 


Novel treatment of hemophilia: OMRF enters license agreement with ... - GlobeNewswire (press release)



Novel treatment of hemophilia: OMRF enters license agreement with ... 
GlobeNewswire (press release)
OKLAHOMA CITY, Feb. 13, 2018 (GLOBE NEWSWIRE) -- The Oklahoma Medical Research Foundation has entered a license agreement with Shanghai RAAS Blood Products Co., Ltd. Under the agreement, Shanghai RAAS has the exclusive rights to develop and market ...

and more » 


Early Analysis Supports Eloctate Use in ITI Therapy for Severe Hemophilia A - Hemophilia News Today



Hemophilia News Today
 
Early Analysis Supports Eloctate Use in ITI Therapy for Severe Hemophilia A 
Hemophilia News Today
However, ITI usually requires patients undergo therapy for an extended period so the immune system learns not to attack the factor VIII being administered. Eloctate is the first extended half-life FVIII approved to treat hemophilia A, but data showing ...

 


How Paper and Scissors Gave Back Dignity to Hemophilia Patients - Sixth Tone



Sixth Tone
 
How Paper and Scissors Gave Back Dignity to Hemophilia Patients 
Sixth Tone
The traditional Chinese craft of paper-cutting is helping people with the blood disorder earn a living.

and more » 


Analyst Lifts Catalyst Biosciences PT From $10 To $75 On Hemophilia B Product - Benzinga



Benzinga
 
Analyst Lifts Catalyst Biosciences PT From $10 To $75 On Hemophilia B Product 
Benzinga
... is 22 times more potent than the current standard care, BeneFIX. The company also reported a "moderate generalized ache and mild subcutaneous (SQ) injection site discomfort in one subject and a brief mild adverse event among two other subjects, the ...
Phase 1/2 data on Catalyst Bio's hemophilia B candidate underwhelms investors, shares down 12% premarket Seeking Alpha
Catalyst Biosciences Announces Positive Top-Line Data from Phase 1/2 Study of Subcutaneous CB 2679d/ISU304 in ... GlobeNewswire (press release)
Catalyst Biosciences (CBIO) PT Raised to $47 at Ladenburg ... StreetInsider.com
Nasdaq  -Analyst Ratings 
all 22 news articles »